ストックスクリーナーアプリを入手
1.54
3.14%
-0.05
アフターアワーズ：
1.54
前日終値:
$1.59
開ける：
$1.62
24時間の取引高:
3.91M
Relative Volume:
0.92
時価総額：
$408.32M
収益：
$194.75M
当期純損益:
$-51.26M
株価収益率:
-5.50
EPS:
-0.28
ネットキャッシュフロー:
$-23.38M
1週間 パフォーマンス:
-12.50%
1か月 パフォーマンス:
-51.27%
6か月 パフォーマンス:
-47.26%
1年 パフォーマンス:
-13.97%
1日の値動き範囲:
$1.525
$1.6555
1週間の範囲:
$1.525
$1.835
52週間の値動き範囲:
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
名前
Akebia Therapeutics Inc
セクター
電話
617-871-2098
住所
245 FIRST STREET, CAMBRIDGE, MA
AKBA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.54 | 421.93M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-04 | 再開されました | H.C. Wainwright | Buy |
| 2025-04-28 | 開始されました | Leerink Partners | Outperform |
| 2025-04-01 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 再開されました | BTIG Research | Buy |
| 2023-08-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-03-31 | ダウングレード | Needham | Buy → Hold |
| 2022-03-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 繰り返されました | Needham | Buy |
| 2019-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-02 | 開始されました | JP Morgan | Overweight |
| 2019-03-20 | 開始されました | Citigroup | Neutral |
| 2018-09-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 繰り返されました | Needham | Buy |
| 2018-06-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-12-19 | 開始されました | Piper Jaffray | Overweight |
| 2017-12-07 | 開始されました | BTIG Research | Buy |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-27 | 繰り返されました | Needham | Buy |
| 2016-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-12-20 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-15 | 開始されました | Aegis Capital | Buy |
| 2016-09-29 | 開始されました | Brean Capital | Buy |
| 2016-03-16 | 繰り返されました | Needham | Buy |
| 2016-01-21 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Akebia Therapeutics Inc (AKBA) 最新ニュース
How forex fluctuations impact Akebia Therapeutics Inc. (AX9) stockWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
How Akebia Therapeutics Inc. stock compares to market leadersPortfolio Risk Summary & Growth Focused Entry Point Reports - newser.com
What analyst consensus implies for Akebia Therapeutics Inc. (AX9) stockCEO Change & AI Forecasted Entry/Exit Points - newser.com
Is Akebia Therapeutics Inc. stock cheap at current valuationBond Market & Weekly High Potential Stock Alerts - newser.com
Live market analysis of Akebia Therapeutics Inc.Portfolio Gains Report & Real-Time Sentiment Analysis - newser.com
How Akebia Therapeutics Inc. (AX9) stock gains from tech spendingTrade Entry Report & Free Verified High Yield Trade Plans - newser.com
How Akebia Therapeutics Inc. (AX9) stock behaves in tightening cyclesMarket Volume Summary & Expert Curated Trade Setups - newser.com
Signal strength of Akebia Therapeutics Inc. stock in tech scannersJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. stock a safe investment in uncertain markets2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock - newser.com
Tools to assess Akebia Therapeutics Inc.’s risk profileJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Brokerages Set Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target at $6.00 - Defense World
This trade activity should not be overlooked: Akebia Therapeutics Inc (AKBA) - Setenews
Levi & Korsinsky Announces an Investigation on Behalf of Akebia Therapeutics, Inc. (AKBA) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
AKBA: Vafseo's expanding access and strong clinical data position it for standard of care in dialysis - TradingView
Akebia Therapeutics, Inc. Announces Amendment to License Agreement for Drug Supply and Manufacturing Rights - MarketScreener
Akebia Therapeutics amends license agreement with Medice for Vafseo supply - Investing.com
Akebia Therapeutics amends license agreement with Medice for Vafseo supply By Investing.com - Investing.com South Africa
Akebia Therapeutics Inc says on Nov 12, co and Medice amend license agreement - MarketScreener
Analyzing Akebia Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Reliable Breakout Stock Forecasts - newser.com
Akebia Therapeutics Shares Extend Decline Amid Analyst Downgrades - Ad-hoc-news.de
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
FY2025 Earnings Forecast for AKBA Issued By Leerink Partnrs - MarketBeat
Akebia Therapeutics Inc. stock retracement – recovery analysisMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Shareholders Alert: Investigation Into Akebia Therapeutics, Inc. (AKBA)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
How Akebia Therapeutics Inc. stock reacts to job market data2025 Price Targets & Community Consensus Picks - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsExit Point & AI Driven Price Predictions - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Akebia Therapeutics Inc (AKBA) 財務データ
収益
当期純利益
現金流量
EPS
6.17%
0.67%
大文字化:
|
ボリューム (24 時間):